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Abstract
Background: Inclusion body myositis (IBM) is a poorly understood and refractory autoimmune muscle disease. Though
widely believed to have no significant humoral autoimmunity, we sought to identify novel autoantibodies with high
specificity for this disease.
Methodology/Principal Findings: Plasma autoantibodies from 65 people, including 25 with IBM, were analyzed by
immunoblots against normal human muscle. Thirteen of 25 (52%) IBM patient samples recognized an approximately 43 kDa
muscle protein. No other disease (N=25) or healthy volunteer (N=15) samples recognized this protein.
Conclusions: Circulating antibodies against a 43-kDa muscle autoantigen may lead to the discovery of a novel biomarker for
IBM. Its high specificity for IBM among patients with autoimmune myopathies furthermore suggests a relationship to
disease pathogenesis.
Citation: Salajegheh M, Lam T, Greenberg SA (2011) Autoantibodies against a 43 KDa Muscle Protein in Inclusion Body Myositis. PLoS ONE 6(5): e20266.
doi:10.1371/journal.pone.0020266
Editor: John A. Chiorini, National Institute of Dental and Craniofacial Research, United States of America
Received January 3, 2011; Accepted April 28, 2011; Published May 23, 2011
Copyright:  2011 Salajegheh et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This study was sponsored by the Muscular Dystrophy Association (grants MDA92561 to Dr. Salajegheh and MDA4353 to Dr. Greenberg) URL: http://
www.mdausa.org/. No additional external funding was received for this study. The named funder had no role in study design, data collection and analysis,
decision to publish, or preparation of the manuscript. Dr. Salajegheh, Ms. Lam and Dr. Greenberg report no further financial disclosures in regards to this study.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: msalajegheh@partners.org
Introduction
The inflammatory myopathies are autoimmune diseases of skeletal
muscle, and consist of three major subtypes: dermatomyositis,
polymyositis, and inclusion body myositis (IBM). Circulating
autoantibodies have been detected in dermatomyositis and polymyo-
sitis (reviewed in [1]) and sought in IBM [2]; however, none have
been reported as prominently present in, or specific to, IBM [3].
Since 1984 [4], IBM has been believed to be a cytotoxic T-cell
mediated disease with no humoral autoimmunity. Microarray
studies reported in 2001, surprisingly showed that the most
abundantly present transcripts in IBM muscle samples compared
to normal muscle were immunoglobulin transcripts, unique to the
B cell lineage [5,6]. This finding led to the demonstration in IBM
muscle of abundant plasma cells [7] with immunoglobulin gene
rearrangements, characteristic of clonal expansion in response to
local antigen stimulation [8], as well as the presence of a
permissive environment for ectopic lymphoid structures suggestive
of local maturation of B cells in muscle [9]. The presence of this
recently elucidated B cell immunopathogenesis provided rationale
for searching for circulating autoantibodies.
In this studywe reportidentificationofa circulatingautoantibody
against a 43-kDa muscle autoantigen that is specific to IBM among
other patients with autoimmune myopathies that we examined.
Results
We performed immunoblots with plasma samples from 25
people with IBM, 25 people with other autoimmune muscle
disease (10 dermatomyositis, 10 polymyositis, and 5 myasthenia
gravis), and 15 healthy volunteers against normal human muscle
lysates. While previous studies have probed myositis blood against
proteins derived from non-muscle sources, such as those prepared
from HeLa cells [10], we sought autoantibodies against proteins
derived from human muscle.
Immunoblots against normal human muscle lysates of blood
samples from 65 people showed reactivity to an approximately
43 kDa muscle protein in 52% (13 of 25) of IBM samples and in
no other autoimmune myopathy or healthy volunteer samples (0 of
40; p,0.0001 Fisher’s exact test) (Figure 1). The detection of a
43 kDa muscle autoantigen thus had a sensitivity of 52% and
specificity of 100% for IBM among 50 patients with autoimmune
myopathies. The approximately 43-kDa band was sometimes (8 of
13 of positive samples) associated with a fainter nearby band, that
may be seen with post-translational modification or partial protein
degradation.
IBM is a disease of middle to late age; our patients with IBM
were therefore older (mean age 68 years) than patients with other
autoimmune myopathies (mean age 48 years), but the presence of
the anti 243 kDa autoantibody did not appear age-associated.
The mean age of the 13 IBM patients with anti-43-kDa
autoantibodies (67 years) did not differ from the mean age of the
13 oldest control patients, none of whom had anti-43-kDa
autoantibodies (64 years; p=0.21 Mann-Whitney test). Even
within the group of IBM, age played no role in the development of
anti-43-kDA autoreactivity, as the mean age of IBM patients with
autoreactivity (67 years) did not differ from those without
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duration was not different between IBM patients demonstrating
43 kDa autoreactivity (6 years) and those without reactivity (8
years; p=0.6 Mann-Whitney test). Gender (p=0.21) and race
(p=1.0) were also not associated with the presence of the 43-kDa
autoantibody when comparing all patients studied (Fisher’s exact
test for both analyses).
Treatment status did not appear to affect autoantibody
detection, even though most patients with IBM were untreated
while most patients with DM and PM received immunomodulat-
ing therapy. Within the group of IBM, the proportion of antibody
positive untreated patients (12 of 21) did not differ from that of
antibody positive treated patients (1 of 4; p=0.32 Fisher’s exact
test). Analysis of data of all untreated patients showed statistically
significant development of autoantibodies in IBM (12 of 21) but
not in other disease controls (0 of 7; p=0.01 Fisher’s exact test for
both comparisons) despite lack of treatment. For the 16 IBM
patients tested for anti-nuclear antibodies (ANA) there was no
relationship between 43 kDa autoreactivity and a positive test for
ANA (p=1 Fisher’s exact test).
Discussion
Autoimmune muscle injury in IBM has been widely believed to
be mediated by cytotoxic T cell mechanisms alone (reviewed in
[11]). The demonstration of antigen-stimulated plasma cell
antibody production [8] and now a circulating IBM autoantibody
against a 43 kDa muscle protein provides compelling evidence for
humoral autoimmunity in IBM. Because of the principal of linked
recognition (B cell aided maturation of T cell requires that both B
cell immunoglobulin and T cell receptor recognize the same
molecular complex), antigens to which autoantibodies are directed
may also be candidates for T cell directed autoimmunity. The
modest sensitivity (52%) but very high specificity (100%) of this
autoantibody, in our group of IBM and other inflammatory
myopathy patients, is a feature shared by many other autoanti-
bodies in myositis [1] [12].
While previous studies have reported an association between
IBM and the presence of various autoantibodies, thus suggesting
an autoimmune process in IBM, none have been identified as
disease specific [13] and their prevalence is less than that seen with
DM and PM [3] [14] [15] [16] [17]. In a review of 99 patients
with sporadic IBM, 43 (44%) had elevated titers of one or more of
nine different non disease-specific autoantibodies [13]. While 8 of
16 (50%) of our IBM patients tested for autoantibodies where
positive for ANA, there was no relationship between this positivity
and the presence of 43 kDa autoreactivity.
The identity of the 43 kDa muscle autoantigen in IBM reported
here, as well as its specificity to muscle tissue, remains to be
determined. Technical aspects of myositis antigen identification
have typically resulted in a several year lag between recognition of
an autoantigen by its weight on immunoblots and its subsequent
definitive identification. For example, recognition of a 140 kDa
autoantigen in dermatomyositis [10] preceded its definitive
identification as IFIH1 by 4 years [18]. The eventual determina-
tion of this IBM autoantigen’s identity may provide understanding
of the pathogenesis of IBM and potentially aid in its diagnosis.
Materials and Methods
Ethics Statement
All samples originating from patients were derived after
informed written consent was obtained and under protocols
approved by the Partners Human Research Committee (PHRC),
the Institutional Review Board (IRB) of Partners Research
Management that is responsible for overseeing all human subject
research conducted by Partners-affiliated investigators (such as
Brigham and Women’s Hospital).
Patient Samples
Plasma samples from 25 patients with IBM (mean/range age
69/50–87 years), 25 patients with other autoimmune myopathies
(mean/range age 48/24–91), and 15 healthy volunteers (mean/
range age 52/34–62 years) were probed against normal human
muscle lysates. Diagnostic criteria for IBM, dermatomyositis, and
polymyositis were as previously described [19]. In particular, all
patients with IBM fulfilled European Neuromuscular Centre
(ENMC) criteria for probable or definite IBM [20]. All healthy
volunteers were required to have been free of any infectious or
inflammatory diseases, the use of immunomodulatory agents or
vaccination at least for six months prior to collection of blood
sample. Detailed description about patients and normal control
characteristics, including age, gender, racial background, disease
and diagnostic workup characteristics, treatment status, treatment
response and 43 kDa muscle protein autoreactivity can be found
in the supplemental tables (Table S1 and Table S2, respectively).
Figure 1. Circulating autoantibodies against a 43 kDa muscle autoantigen in inclusion body myositis (IBM). Images from all
immunoblots are shown. Reactivity is present in 13 of 25 different inclusion body myositis (IBM) plasma samples, but in none of 10 dermatomyositis
(DM), 10 polymyositis (PM), 5 myasthenia gravis (MG) or 15 normal volunteer (NL) plasma samples.
doi:10.1371/journal.pone.0020266.g001
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Muscle lysates were prepared and probed as previously
described [19]. Briefly, 5 mg of cryostat sectioned normal human
muscle was dounce homogenized in 200 ml of lysis buffer
(containing 10 mM HEPES, 10 mM KCl, 1 mM EDTA,
0.1 mM EGTA, 10 mM DTT, 5 mM MgCl2 and Roche
Complete Protease Inhibitor) and centrifuged at 2,000 g for
10 minutes at 4uC. The supernatant was removed and 30 mg
loaded in individual wells of 4–12% NuPAGE Novex Bis-Tris Gels
(cat# NP0322BOX, Invitrogen). Proteins were separated using
SDS-PAGE and transferred to a nitrocellulose membrane. We
used human plasma (1:1000 dilution) as primary antibody and
goat anti human-IgG HRP (cat# 31410, Pierce Biotechnology,
1:60,0000 dilution) as secondary antibody, both for 1 hour at
room temperature. Blots were developed using the SuperSignal
West Pico kit (cat# 34077, Pierce Biotechnology, 5 min, room
temperature).
Statistical Analysis
To demonstrate the presence of selective immunoreactivity
against a 43 kDa muscle protein in plasma of patients with IBM,
compared with disease controls and healthy volunteers, as well as
determining the effects of gender, treatment, race and ANA
positivity on such reactivity we used the Fisher’s exact test. We
used the non-parametric Mann-Whitney test to determine the
effect of age and disease duration on plasma immunoreactivity
against the 43 kDa muscle protein.
Supporting Information
Table S1 Patient characteristics for 25 inclusion body myositis
(IBM), 10 dermatomyositis (DM), 10 polymyositis (PM) and 5
myasthenia gravis (MG) patients.
(XLS)
Table S2 Characteristics for 15 normal volunteers.
(XLS)
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